-
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody Workflow
2026-09-03
Build sensitive rabbit-primary staining workflows for immunofluorescence, IHC, ICC, and flow cytometry with a light-protected Cy3-conjugated secondary antibody. This guide connects practical assay design to a NETs toxicology study, while emphasizing controls, quantitative readouts, and troubleshooting rather than unsupported performance claims.
-
Hippo Signaling Directs Hepatobiliary Maturation
2026-09-03
This preprint identifies two spatially and temporally distinct Hippo pathway modules that regulate hepatocyte and cholangiocyte maturation rather than simply controlling liver size. Its combination of mouse genetic perturbation, spatial transcriptomics, and imaging provides a framework for interpreting immature hepatobiliary cell states during development and regeneration.
-
SU5416 (Semaxanib): Reliable Assay Workflows
2026-09-02
This scenario-based guide helps researchers use SU5416 (Semaxanib), SKU A3847, in endothelial proliferation, viability, cytotoxicity, and angiogenesis workflows. It covers concentration design, DMSO compatibility, interpretation of VEGFR2-dependent effects, HIF1α-related confounding, and practical vendor-selection criteria.
-
Cy3 Rabbit Anti-Goat IgG (H+L) Antibody Guide
2026-09-02
The Cy3 Rabbit Anti-Goat IgG (H+L) Antibody provides fluorescent detection of goat IgG primary antibodies in ICC/IF, frozen or paraffin IHC, flow cytometry, and fluorescence-compatible ELISA. It should not be used as a universal secondary antibody for non-goat primaries, non-IgG targets, or unvalidated live-cell workflows.
-
Doxorubicin: From DNA Damage to Cardiac Insight
2026-09-01
Doxorubicin hydrochloride and Adriamycin HCl remain valuable translational tools because the same mechanisms that drive tumor-cell killing can expose cardiac liabilities. This thought-leadership guide connects DNA damage, energy stress, apoptosis, and the emerging ATF4–CSE–H2S cardioprotection hypothesis to more decision-ready cancer and cardiotoxicity workflows.
-
Clarithromycin and CYP3A: Translational Design
2026-09-01
A mechanistic and strategic guide to using Clarithromycin as a CYP3A inhibitor in drug-drug interaction research, pharmacokinetic studies, and cardiovascular translation. The article explains how to design interpretable experiments, position CYP3A-independent comparators, and avoid overextending in vitro findings into clinical conclusions.
-
CSBTA Pharmacokinetics in MASH Mice
2026-08-31
The reference study integrates pharmacokinetics, tissue distribution, transporter assays, microsomal metabolism, and PXR-related analysis to explain how MASH alters exposure to three major Corydalis saxicola Bunting total alkaloids. Its central finding is that HFHCD-induced disease and repeated dosing increase systemic and hepatic exposure, providing a mechanistic basis for dose variability in MASLD/MASH treatment.
-
2-Hydroxypropyl-β-cyclodextrin Workflow Guide
2026-08-31
2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide for handling poorly water-soluble hydrophobic compounds, particularly molecules containing aromatic or phenyl groups. This guide focuses on pharmaceutical solubility improvement, drug formulation excipient workflows, and biochemical formulation studies; it does not establish therapeutic efficacy or support unrelated applications.
-
Protease Inhibitor Cocktail for Plant Assays
2026-08-30
Discover how a Protease Inhibitor Cocktail supports protein stability in plant extracts while improving interpretation of symbiosis and flavonoid-signaling assays. This guide connects inhibitor selection, EDTA-free chemistry, and the NSP2–MYB40 research framework to practical workflow decisions.
-
ARID1A-Linked Melanoma Resistance Networks
2026-08-29
The reference study integrates transcriptional, proteomic, and signaling data to define how ARID1A loss rewires melanoma responses to BRAF/MAPK inhibition. Its identification of PRKD1, JUN, and NCK1 as resistance-associated network nodes connects persistent kinase activity with immune-related and extracellular-matrix changes, providing a mechanistic framework for cancer biology and metastatic melanoma research.
-
Chloramphenicol for Plasmid Transfer Assays
2026-08-28
Use Chloramphenicol as a controlled selection tool for plasmid maintenance, conjugation screens, and resistance-gene workflow validation. This guide connects practical assay design with recent evidence on carbapenemase-encoding gene transmission in Enterobacter cloacae while emphasizing orthogonal confirmation and troubleshooting.
-
Iron Stress Reprograms Enterocyte Metabolism
2026-08-28
Navazesh and Ji used paired iron-deficiency and iron-excess models in IPEC-J2 enterocytes to show that iron imbalance produces distinct transcriptional, inflammatory, and metabolic states. Their integration of time-course gene analysis, LPS challenge, and untargeted metabolomics provides a useful framework for studying intestinal iron homeostasis and metabolic resilience.
-
Triptolide (PG490): Mechanisms and Research Use
2026-08-27
Triptolide, also known as PG490, is a nanomolar-potency natural product used in cancer research, immunology, and inflammation studies. Its reported actions include IL-2 suppression, NF-κB transcriptional inhibition, CDK7-associated RNA polymerase II loss, matrix metalloproteinase reduction, and apoptosis induction.
-
InstaBlue Protein Stain Solution Workflow
2026-08-27
Build a rapid, solvent-free gel workflow for antibody expression checks, variant comparison, and MS-oriented band selection. InstaBlue Protein Stain Solution delivers visible Coomassie contrast in minutes while preserving a practical path to downstream protein characterization.
-
Meropenem: Mechanism and Infection Research
2026-08-26
Meropenem is a β-lactam antibiotic carbapenem that inhibits bacterial cell-wall synthesis through penicillin-binding proteins. Its broad in vitro activity supports Gram-negative bacterial infection models, while recent carbapenem-resistance data show why susceptibility and resistance-gene testing must accompany experimental use.